Results 131 to 140 of about 131,254 (306)
Engraftment of sheep splenic lymphocytes into NBSGW mice and application in Brucella infection
Animal Models and Experimental Medicine, EarlyView.A sheep splenocyte‐reconstituted mouse model (Sh‐Spl mice) was established via intravenous injection of sheep splenic lymphocytes into immunodeficient mice to evaluate Brucella infection. Abstract Background The development of immune reconstituted xenograft mouse models has addressed the limitations imposed by interspecies immunological differences in ...
Xiaowei Wang +9 more
wiley +1 more source
Chimeric antigen receptor preparation from hybridoma to T-cell expression
, 2019 The successful use of chimeric antigen receptor (CAR) for hematological cancer treatment has influenced the direction taken in translational research toward an increasing focus on personalized targeted immunotherapy.
Warren, David +5 more
core +1 more source
Advances and perspectives in animal models of human hepatitis A virus
Animal Models and Experimental Medicine, EarlyView.Following HAV infection, humans, non‐human primates, and Ifnar1−/− mice develop characteristic manifestations of hepatitis A, including fecal viral shedding, elevated serum ALT levels, and inflammatory cell infiltration in the liver. In contrast, HAV‐infected human liver chimeric mice exhibit fecal viral shedding but do not develop clinical features of
Jian Li +3 more
wiley +1 more source
, 2016 Preparation of chimeric antigen receptor-modified (CAR) T cells targeting CD19 (CART19).
Chengfei Pu (3443966) +11 more
core +1 more source
Animal models of idiopathic membranous nephropathy: Recent advances and future perspectives
Animal Models and Experimental Medicine, EarlyView.This review focuses on the evolution of idiopathic membranous nephropathy (IMN) animal models from traditional approaches (Heymann nephritis, C‐BSA, APA) to antigen‐specific models (PLA2R, THSD7A), critically evaluating their advances and limitations in replicating human IMN pathology.
Qiuying Liu +6 more
wiley +1 more source
Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma
, 2019 CD19 Chimeric antigen receptor (CAR) T cell therapy has been shown to be effective for B cell leukemia and lymphoma. Many researchers are now trying to develop CAR T cells for various types of cancer. For multiple myeloma (MM), B-cell maturation antigen (
Naoki Hosen
core +1 more source
Therapeutic Applications of Stimuli‐Based Release and Engineering of Extracellular Vesicles
Advanced NanoBiomed Research, EarlyView.This review summarizes the effects of endogenous and exogenous stimuli, their effects on the natural release of extracellular vesicles, as well as their uptake and release. It also gives an overview of stimuli‐responsive EVs and their therapeutic applications. Extracellular vesicles (EVs), nano‐ to microsized lipid bilayer membrane‐bound particles, are
Gloria Kemunto, Kristen Dellinger
wiley +1 more source
Chimeric antigen receptor T-cell therapy
, 2019 Although treatment of haematological cancer has improved significantly during the latest decades, the prognosis is poor in case of relapse or refractory disease.
Met, Özcan +5 more
core
Advanced NanoBiomed Research, EarlyView.CRISPR/Cas9 has revolutionized the field of gene therapy, but delivery remains an outstanding issue. We propose a nonviral gold‐nanoparticle platform for co‐delivery of CRISPR/Cas9 ribonucleoprotein and long 2.1 kilobase dsDNA transgene constructs. This CRISPR‐AuNP is inexpensive to produce and mediate gene editing and DNA delivery in T cells and CD34+
Rachel A. Cunningham +8 more
wiley +1 more source
Chimeric antigen receptor modified T-cells for cancer treatment
, 2018 T cells engineered with the chimeric antigen receptor (CAR) are rapidly emerging as an important immunotherapy for hematologic malignancies. The anti-cluster of differentiation (CD)19 CAR-T cell therapy has been remarkably successful against refractory ...
Xiao Han +3 more
core +1 more source